Contents

Search

deferoxamine infusion test

Indications: - alumininum toxicity, serum aluminum > 60 ng/mL (prior to dialysis) Procedure: - infusion of 5 mg/kg of desferoxamine IV over 20 minutes or more post dialysis - an increase in serum aluminum > 150 ng/mL with sample prior to next dialysis session

Related

aluminum toxicity deferoxamine (Desferal)

General

clinical procedure

References

  1. Milliner DS et al Use of the deferoxamine infusion test in the diagnosis of aluminum-related osteodystrophy. Ann Intern Med. 1984 Dec;101(6):775-9. PMID: 6208838
  2. DESFERAL: Novartis Pharmaceuticals http://www.rxmed.com/b.main/b2.pharmaceutical/b2.1.monographs/CPS-%20Monographs/CPS-%20(General%20Monographs-%20D)/DESFERAL.html